Peritumoral administration of IFNβ upregulated mesenchymal stem cells inhibits tumor growth in an orthotopic, immunocompetent rat glioma model

BACKGROUND: Immunotherapy with IFNβ is a promising strategy for treating malignant glioma. However, systemic administration of IFNβ is inadequate because of low intratumoral concentration and major adverse effects. This study aimed to determine whether mesenchymal stem cells (MSCs) can be used as ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Jiaji, Cao, Minghui, Zhang, Fang, Zhang, Jingzhong, Duan, Xiaohui, Lu, Liejing, Yang, Zehong, Zhang, Xiang, Zhu, Wangshu, Zhang, Qinyuan, Wang, Zhe, Shen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069318/
https://www.ncbi.nlm.nih.gov/pubmed/32169868
http://dx.doi.org/10.1136/jitc-2019-000164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069318/
https://www.ncbi.nlm.nih.gov/pubmed/32169868
http://dx.doi.org/10.1136/jitc-2019-000164

Ejemplares similares